Shelton Capital Management’s 10x Genomics TXG Stock Holding History

Shelton Capital Management’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-19,300	Closed	-$2.88M	–	873
2021 Q4	$2.88M	Hold	19,300	–	–	0.1%	201
2021 Q3	$2.81M	Buy	19,300 +2,300	+14%	+$395K	0.11%	192
2021 Q2	$3.33M	Hold	17,000	–	–	0.13%	178
2021 Q1	$3.08M	Buy	17,000 +5,000	+42%	+$863K	0.11%	186
2020 Q4	$1.7M	Buy	12,000 +4,600	+62%	+$668K	0.08%	219
2020 Q3	$923K	Buy	+7,400	New	+$777K	0.04%	358

Other funds holding TXG

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

1WCM

12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return

FCMI

Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Shelton Capital Management's TXG Position: Q1 2022 in Review

Shelton Capital Management sold out of 10x Genomics (TXG) in Q1 2022, closing a stake of 19,300 shares — an estimated $2.88M sold.

Shelton Capital Management first reported a position in TXG in Q3 2020 and held it in 6 quarters. The position peaked at $3.33M in Q2 2021. 314 funds tracked by Wall St. Rank hold TXG as of Q1 2022.

Shelton Capital Management reported no remaining 10x Genomics position as of Q1 2022 after selling out during the quarter.
Shelton Capital Management sold 19,300 10x Genomics shares in Q1 2022, an estimated $2.88M.
Shelton Capital Management first reported a position in 10x Genomics in Q3 2020 and held it in 6 quarters.
Shelton Capital Management's 10x Genomics position peaked at $3.33M in Q2 2021.
314 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2022.

Based on Shelton Capital Management's 13F filing for Q1 2022, filed 12 May 2022.